ReviewBritish journal of clinical pharmacology2023
Pharmacovigilance in China: Evolution and future challenges.
Review in British journal of clinical pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Glutathione in Skin Aging and Tissue Regeneration: A Systematic Review of Molecular Mechanisms, Redox Modulation, and Biomedical Implications.Molecules (Basel, Switzerland) · 2026Pooled it
- Levofloxacin-Induced Cutaneous Adverse Reactions: Characteristics and Rational Use Strategies.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
- A case of levofloxacin injection-induced lower limb edema.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Navigating Non-interventional Post-authorization Studies in East Asia: Regulatory Challenges, Opportunities, and Future Directions.Drug safety · 2026Review
- Global pharmacovigilance analysis of antimicrobials used in periodontal therapy: safety profiles of minocycline, doxycycline, and chlorhexidine.Head & face medicine · 2026Article
- Analysing lithium, quetiapine and valproic acid on social media: an infodemiology study.International journal of bipolar disorders · 2025Article
- Post-marketing safety evaluation of Guhong Injection: a multicenter, prospective real-world study of 30,000 cases in China.BMC complementary medicine and therapies · 2025Article
- Unveiling Social Media Content Related to ADHD Treatment: Machine Learning Study Using X's Posts over 15 Years.Healthcare (Basel, Switzerland) · 2025Article
- What Affects the Quality of Pharmacovigilance? Insights From Qualitative Comparative Analysis.Pharmacology research & perspectives · 2025Article
- Understanding social media discourse on antidepressants: unsupervised and sentiment analysis using X.European psychiatry : the journal of the Association of European Psychiatrists · 2025Article
- Temporal trends in the incidence of adverse effects of medical treatment in BRICS countries from 1990 to 2021: an age-period cohort analysis.Frontiers in public health · 2025Article
- Quantitative evaluation and obstacle factor diagnosis of drug regulatory capacity in China.PloS one · 2025Article
- Knowledge, attitude, and practice regarding pharmacovigilance among hospital pharmacists in China.Therapeutic advances in drug safety · 2025Article
- A comprehensive analysis of adverse drug reactions in 2020-2023: case studies.Frontiers in pharmacology · 2025Article
- Exploration of adverse event profiles for glofitamab: A disproportionality analysis using the FDA adverse event reporting system.PloS one · 2025Article
- Development and validation of a predictive nomogram for severe adverse drug reactions: a dual-center pharmacovigilance study.Frontiers in pharmacology · 2025Article
- Article
- Article
- Strengths and weaknesses of current and future prospects of artificial intelligence-mounted technologies applied in the development of pharmaceutical products and services.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Review
- Unveiling quality of clinical trial in China: from concern to confirmation.Cancer communications (London, England) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Drug-related adverse reactions are among the main reasons for harm to patients under care worldwide and even their deaths. The pharmacovigilance system has been proven to be an effective method of avoiding or alleviating such adverse events. In 2019, after two decades of implementation of the drug-related adverse reaction reporting system, China formally implemented a pharmacovigilance system with the Pharmacovigilance Quality Management Standards and a series of supporting technical documents created to improve the safety of medication given to patients. China's pharmacovigilance system has faced many problems and challenges during its implementation. This spontaneous reporting system is the main source of data for China's medication vigilance activities, but it has not provided sufficiently powerful evidence for regulatory decision-making. In conformity with the health-centred drug regulatory concept, the Chinese government has accelerated the speed of examination and approval of urgently needed clinical drugs and orphan drugs along with the requirement to improve the safety supervision of these drugs after their listing. China's marketing authorization holders (MAHs) must strengthen their pharmacovigilance capabilities as the primary responsible departments for drug safety. Chinese medical schools generally lack professional courses on pharmacovigilance. The regulatory authorities have recognized such problems and have made efforts to improve the professional capacity of pharmacovigilance personnel and to strengthen cooperation with stakeholders through the implementation of an action plan of medication surveillance and the establishment of a patient-based adverse events reporting system and active surveillance systems, which will help China bridge the gap to bring its pharmacovigilance practice up to standards.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.